

#### THE VACCINE PRODUCT PRICE AND PROCUREMENT PROJECT

# Improving access to vaccines: the role and progress of vaccine price transparency

Stephanie Mariat WHO/FWC/IVB/EPI

08 March 2017



PART 1: Why price transparency?

PART 2: The role of WHO

PART 3: V3P - progress and use

PART 4: Moving forward





The role and progress of vaccine price transparency - 08 March 2017



## Vaccine price is an important element of sustainable immunization programmes

- Vaccine price is an important component of immunization budgets: 81.5%
- Required budget is a major factor in decisions to adopt and to sustain new vaccines
- BUT countries lack visibility into vaccine prices for decision making
- Some countries are uncertain about whether they are getting equitable and fair prices

#### Vaccine price is an important component of immunization budgets

Indicator	Measure
Government Expenditure on Vaccines	28.41 USD per live birth
Government Expenditure on Routine Immunization	34.85 USD per live birth
% Government Expenditure on RI spent on Vaccines	81.54%

Sources: JRF 2016 (2015 data). Note that the figures may be significantly different from the previous years due to some changes in methodology and updated/corrected data. Figures are only reflective of the 107 countries that have been included in the final cohort for analysis.








# The cost to fully immunize a child has risen in the last 15 years

- New antigens are added to national programmes (eg. PCV, Rotavirus, HPV, ...)
- Newer vaccines are priced much higher (eg. minimum price available to UNICEF for BCG at \$8c a dose in 2017, while PCV is at \$3.30)






\*Minimum price published on the UNICEF website, mostly offered to Gavi countries Sources: UNICEF vaccine prices



## **Countries face different challenges regarding access to vaccine prices**









## There have been repeated requests for price transparency at the World Health Assembly (WHA)


Since 2001	World Health Assembly asking for <b>increased availability of vaccine pricing information</b>
2014	Request for greater price transparency and
WHA	information on <b>cost of production</b>
2015	Resolution 68.6 on the GVAP* - access to
WHA	sustainable supplies of affordable
	vaccines, including the promotion of
	vaccine <b>price transparency</b>

\* GVAP: Global Vaccine Action Plan Sources: WHA/54, WHA/66, WHA/67, WHA/68



countries in the area of procurement and vaccine

affordability.





PAGE 6



## **SAGE and the World Health Assembly have recommended** countries to share vaccine prices with WHO

Recommendations issued by SAGE in 2014:

"Countries are requested to change the rules of the game on vaccine" affordability, to create transparency which is in their interest. They can do this by making pricing information publicly available, and by collaborating with WHO and all technical agencies to develop solutions."

## Resolution adopted by the 68<sup>th</sup> World Health Assembly in 2015:

The WHA urges member states "to provide, where possible and available, timely vaccine price data to WHO for publication, with the goal of increasing affordability through improved price transparency, particularly for the new vaccines." - Resolution 68.6 on the GVAP











PART 1: Why price transparency?

PART 2: The role of WHO

PART 3: V3P - progress and use

PART 4: Moving forward





The role and progress of vaccine price transparency - 08 March 2017



## The MIC strategy recognizes price transparency as a core activity to support access to vaccines



- Strategy developed in 2015 in collaboration with 8 partners, to support non-Gavi MICs
- + Four main areas of action have been identified by the MIC Strategy:

Goal	Enhance sustainable access to vaccines for populations in middle-income countries to meet GVAP targets			
Driving Principles	<ul> <li>Uphold GVAP principles of country ownership, shared responsibility, integration, sustainability and innovation.</li> <li>Address inequities within and among countries</li> <li>Maximize health impact</li> <li>Consider technical and political feasibility</li> <li>Maximize value for money by complementing existing and planned efforts</li> </ul>			
Geography	All MICs not supported through the Gavi Alliance			
Objective	Raise and sustain high and equitable immunization coverage and enable new vaccine introductions			
Focus areas	<ul> <li>(1) Strengthened decision-making for timely and evidence-based immunization policy and programmatic choices</li> <li>(2) Increased political commitment and financial sustainability of immunization programmes</li> <li>(3) Enhanced demand for and equitable delivery of immunization services</li> <li>(3) Enhanced demand for and equitable delivery of immunization services</li> <li>(4) Improved and affordable and strengthening NITAGs</li> <li>(5) Strengthening national capacity to generate evidence for decision-making</li> <li>(1) Increasing MICs funding credibility through innovative financial platforms</li> </ul>	d timely y ement dge to duct choice cesses nformation lons are or purpose		
Strategic enablers	<ul> <li>Country commitment and cost sharing</li> <li>Coordination among international and local partners</li> <li>International and national advocacy and country-to-country peer learning</li> <li>Strong monitoring and evaluation efforts</li> </ul>			





# WHO has taken a lead role as broker of price transparency through V3P

V3P has been created to help countries gain access to up-to-date vaccine product, price, and procurement information.

It has three main components:




 Price database: to compare prices across countries



 <u>Knowledge repository</u>: to get information about the V3P project and related articles, reports and analyses



 <u>Resource gateway</u>: to access the full range of online resources on vaccine products, prices, and procurement (incl. links to partners' websites)




#### www.who.int/immunization/v3p







## The V3P price database is a collaborative platform for all countries to access and use




\*Pan American Health Organization Revolving Fund





## A standardized process to achieve sustainability of price transparency is in place







# Several immunization partners are active on vaccine price transparency



The role and progress of vaccine price transparency - 08 March 2017





PART 1: Why price transparency?

PART 2: The role of WHO

PART 3: V3P - progress and use

PART 4: Moving forward






The role and progress of vaccine price transparency - 08 March 2017




## Participation of countries in V3P has doubled in 2 years







## In 2016, vaccine price transparency is achieved for 70% of the world



Note: "PAHO" includes all countries of the region of the Americas, as they could all potentially access vaccines through the Revolving Fund. "UNICEF" includes all countries that are Gavi eligible or in-transition and known to procure all or part of their vaccines through UNICEF in 2016.




Organization



# There is good availability of information for LICs and MICs

## Countries covered by the V3P database\*, by income level and Gavi eligibility

Percentage



 Good visibility on prices paid in MICs and LICs


 But data missing for 40% of non-Gavi MICs (27 countries) and 54% of HICs (31 countries)

□ Countries covered by V3P (incl. data from PAHO, UNICEF and countries)

<u>Note</u>: for PAHO, all countries of the AMRO region are included as they could potentially access vaccines through the Revolving Fund. The exact list of the 40 countries purchasing through the revolving fund is not known \* Including data from PAHO, UNICEF and countries




# At the national level, data can be used to inform countries' decisions







## 1 *Decisions & planning*: example of aP & wPcontaining vaccines



Using price information for decision-making:

- + Many MICs are switching from wP-containing products to aP-containing products.
- Countries need to take into account in their decision the high difference in price between these vaccine products.

\*Weighted Average Price, USD per dose. Note that the percentage ca be greater than 100% if a country uses both wP and aP-containing vaccines



## At the global level, data can be used to monitor trends

### Main findings from the GVAP price report

 Pool procurement mechanisms manage to secure lower prices than self-procuring countries, except for self-procuring countries purchasing large volumes.

+ **A small but consistent impact of volume on price** for most vaccines.

 Tiered-pricing: price differentiation led by <u>income segmentation</u> + product preferences (eg. aP vs wP-containing vaccines).





## At the global and regional levels, data can be used to inform strategies

Type of use	Examples
Global market analyses	<ul> <li>GVAP price report, vaccine specific analyses, trends.</li> </ul>
Inform immunization partners policies and market shaping strategies	<ul> <li>What prices will Gavi countries access as they lose external support? What impact market strategies may have on the overall market ?</li> </ul>
Inform regional strategies for access to supply	<ul> <li>Prevalence of single sources of vaccines in European countries.</li> </ul>
Fill in information gap for	<ul> <li>Informing procurement costs and negotiations</li> </ul>

Fill in information gap for international procurement

 Informing procurement costs and negotiations for the purchase of hexavalent vaccine for vaccination of refugees coming to Europe.





## The V3P website is freely accessible









PART 1: Why price transparency?

PART 2: The role of WHO

PART 3: V3P - progress and use

PART 4: Moving forward





The role and progress of vaccine price transparency - 08 March 2017



## Great progress in 2016, which needs to be built upon

## **Strengths**

- 51 countries, 5 WHO regions + PAHO, 5000 users, 45 vaccine types, data for 70% of the world
- Unique, global, coordinated vaccine price database
- + Easy access to data and analyses

### Weaknesses

- + 58 countries still not participating
- Imbalance between regions
- Variable data quality
- Subnational procurement data not captured
- + Cost to countries, not to end users

## **Opportunities**

- WHA resolution + recommendations
- Improve country decision-making and allocation of resources
- + Data collection with the JRF in 2017

### Threats

 Need to make sure that data is used in context as much as possible





## **Moving forward**

- Price transparency is important for countries to take informed decisions for sustainable introduction of new vaccines. It also help countries enhance efficient use of scarce resources.
- Through its price transparency initiative (V3P), WHO is responding to requests by member states for increased price transparency (WHA 68.6)
- In 2016, the V3P database is covering about 70% of the world, both in terms of number of countries and birth cohort.
- Collected data is already useful to inform understanding of vaccine markets and for global policy making.
- Moving forward, efforts will focus on maintaining participation and enhancing country use of information.





## **Thank you!**

# WEB: www.who.int/immunization/v3p EMAIL: v3p-project@who.int

World Health Organization

26